Cite
Data from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
MLA
Jaime R. Merchan, et al. Data from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6ca5ec88809267603808877f8531d143&authtype=sso&custid=ns315887.
APA
Jaime R. Merchan, Caio Rocha-Lima, Pasquale Benedetto, Jonathan C. Trent, Krisztina Kovacs, Aurea Flores, Deukwoo Kwon, & Alberto J. Montero. (2023). Data from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Chicago
Jaime R. Merchan, Caio Rocha-Lima, Pasquale Benedetto, Jonathan C. Trent, Krisztina Kovacs, Aurea Flores, Deukwoo Kwon, and Alberto J. Montero. 2023. “Data from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....6ca5ec88809267603808877f8531d143&authtype=sso&custid=ns315887.